cgn
CGN
Ocugen Inc
(OCGN)
Follow
FY2023 8 K
View More
FY2023 8 K
Filing:
8 K
Published on:
9 Nov '23
Nasdaq Notice
3 Jan '25
Investor Presentation
3 Dec '24
Management Change
15 Nov '24
Investor Presentation
12 Nov '24
Loan Agreement
8 Nov '24
Financial Results
8 Nov '24
Investor Presentation
13 Aug '24
Earnings Calls
8 Aug '24
FDA Notification for Expand...
5 Aug '24
Public Offering
1 Aug '24
Appointment of Pricewaterho...
8 Jul '24
8-K Filing
28 Jun '24
Accounting Firm Change
6 Jun '24
Financial Results Announcement
14 May '24
Dividend Declaration
10 May '24
Litigation Dismissal
29 Apr '24
FDA Clearance for Phase 3 T...
8 Apr '24
Earnings Calls
2 Apr '24
Restatement of Financial St...
1 Apr '24
Litigation Dismissal
21 Mar '24
Departure of Directors and ...
20 Mar '24
Appointment
18 Mar '24
Presentation at Clinical Sh...
21 Feb '24
Stock Grants
8 Jan '24
Other Events
22 Dec '23
Presentation
9 Nov '23
Earnings Calls
9 Nov '23
Delisting
1 Nov '23
Other Special Situation
10 Oct '23
Appointment of Interim Chie...
19 Sep '23
Clinical Study Update
13 Sep '23
Earnings Calls
22 Aug '23
Earnings Calls
21 Aug '23
Management Changes
15 Aug '23
Annual Meeting Results
27 Jun '23
Presentation at BIO Interna...
5 Jun '23
Underwriting Agreement
25 May '23
Other Events
5 May '23
Results of Operations and F...
5 May '23
Positive Preliminary Data a...
14 Apr '23
Presentation
13 Mar '23
Resignation of Chief Accoun...
10 Mar '23
Appointment and Lawsuit Dis...
6 Mar '23
Earnings Calls
28 Feb '23
Presentation
6 Feb '23
Presentation
9 Jan '23
Other Special Situation
9 Jan '23
External Links:
SEC